DOES RYGB ALTER CIRCULATING GUT-DERIVED PEPTIDES IN MORBIDLY OBESE PATIENTS

RYGB 是否会改变病态肥胖患者的循环肠道衍生肽

• 批准号: 8365478
• 负责人: ROBERT N. COONEY
• 金额: $ 5.74万
• 依托单位: BATTELLE PACIFIC NORTHWEST LABORATORIES
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8365478
• 关键词: American; Amputation; Anatomy; Biology; Blindness; Data; Diabetes Mellitus; End stage renal failure; Endocrine; Fasting; Funding; Future; Grant; Intestines; Limb structure; Mediator of activation protein; Medical; Metabolism; National Center for Research Resources; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Patients; Peptides; Plasma; Positioning Attribute; Principal Investigator; Proteomics; Publications; Research; Research Infrastructure; Resolution; Resources; Source; Tissue Banking; Tissue Banks; Tissue Sample; United States National Institutes of Health; base; cost; effective therapy; improved

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Obesity is associated with numerous medical conditions, the most devastating of which is diabetes (T2DM). Ove 15 million Americans are afflicted with T2DM which represents the leading cause of end-stage renal disease, blindness, and non-traumatic limb amputation. Recent evidence suggests RYGB to be the most effective treatment available for patients with T2DM. Resolution of T2DM is noted in over 80% of obese patients after RYGB. Post-RYGB improvements in T2DM appear to be the result of changes in gut anatomy which influence intestinal metabolism and endocrine function. Despite this important observation, our current understanding of how changes in gut anatomy improve T2DM is limited. We hypothesize that proteomic analyses of pre- and post-RYGB fasting and post-prandial plasma in patients ¿ T2DM will enhance our understanding of how changes in gut anatomy improve T2DM. Based on our established tissue bank containing longitudinal pre- and post-RYGB tissue samples we are in a unique position to collaborate with PNNL and perform these studies. Furthermore, preliminary proteomic analysis of fasting plasma from pre- and post-RYGB patients support this hypothesis and provide proof of concept. The proposed studies have the potential to dramatically influence our understanding of how RYGB improves T2DM and potentially identify new medical therapies. In addition we anticipate they will identify potential mediators for future study, generate preliminary data for future grant submission and scientific data for publication.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持 并且子项目的主要研究者可能是由其他来源提供的， 包括其他 NIH 来源。 子项目可能列出的总成本 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 肥胖与多种疾病有关，其中最具破坏性的是糖尿病（T2DM）。超过 1500 万美国人患有 T2DM，这是导致终末期肾病、失明和非创伤性截肢的主要原因。最近的证据表明 RYGB 是 T2DM 患者最有效的治疗方法。 RYGB 后，超过 80% 的肥胖患者的 T2DM 得到缓解。 RYGB 后 T2DM 的改善似乎是肠道解剖结构变化的结果，影响肠道代谢和内分泌功能。尽管有这一重要的观察结果，但我们目前对肠道解剖结构的变化如何改善 T2DM 的理解仍然有限。我们假设，对 T2DM 患者 RYGB 前后的空腹和餐后血浆进行蛋白质组学分析，将增强我们对肠道解剖结构的变化如何改善 T2DM 的理解。基于我们建立的包含 RYGB 前后纵向组织样本的组织库，我们处于与 PNNL 合作并开展这些研究的独特地位。此外，对 RYGB 治疗前和治疗后患者的空腹血浆进行的初步蛋白质组学分析支持了这一假设并提供了概念证明。拟议的研究有可能极大地影响我们对 RYGB 如何改善 T2DM 的理解，并有可能确定新的医学疗法。此外，我们预计他们将确定未来研究的潜在中介因素，为未来的拨款申请生成初步数据以及用于出版的科学数据。